Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Income towards Common Stockholders: 2022-2025

Historic Net Income towards Common Stockholders for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$54.9 million.

  • Centessa Pharmaceuticals' Net Income towards Common Stockholders fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Net Income towards Common Stockholders stood at -$54.9 million, which was down 9.03% from -$50.3 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Net Income towards Common Stockholders peaked at -$24.9 million during Q2 2023, and registered a low of -$111.3 million during Q4 2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$47.1 million, with a median of -$42.6 million in 2024.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 61.51% in 2023, then tumbled by 202.22% in 2024.
  • Over the past 4 years, Centessa Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$43.2 million in 2022, then rose by 14.68% to -$36.8 million in 2023, then crashed by 202.22% to -$111.3 million in 2024, then dropped by 28.96% to -$54.9 million in 2025.
  • Its last three reported values are -$54.9 million in Q3 2025, -$50.3 million for Q2 2025, and -$26.1 million during Q1 2025.